StreetAlpha.app
Home › Stocks › OABI

OmniAb, Inc. (OABI)

Healthcare
$5.05
▲ +3.27%
LAST CLOSE · NOV 17

OmniAb licenses an antibody discovery platform to drug developers and academic institutions. It last closed at $5.05 on Nov 17, up 3.27% on the day. OABI last reported earnings on Fri, Oct 30, 2026. The average 12-month price target from 2 analysts is $9.00 (+78.2% from the last close), with a high of $12.00 and a low of $6.00. In the past 30 days there were 1 dark pool print totaling $132K, the largest $132K.

AI Auto Pilots
Is OABI in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$40.2M
+90.6% vs a year ago
Net income
−$43.5M
−108.1% margin
EPS (diluted)
−$0.34
Free cash flow
$2.4M
5.9% margin
Valuation
Market cap
$736.6M
145.9M shares
P/E
–
No P/E while losing money
Price to sales
18.3
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$22.9M
At Sep 30
Shareholder equity
$249.2M
Shares outstanding
145.9M
At Oct 23
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $34.7M$34.7MFY2021FY2022: $59.1M$59.1MFY2022FY2023: $34.2M$34.2MFY2023FY2024: $26.4M$26.4MFY2024FY2025: $18.7M$18.7MFY2025

From OABI's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 30). Last 12 months adds up the four latest quarters.

Last report
Oct 30
2026 · Before the open (BMO)
Reported EPS
-$0.12
vs -$0.12 est. · inline
Year-ago EPS
—
Not on file
Options-implied move
±9.6%
Priced in before that report
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated OABI in the past 90 days, not enough for a consensus
Average 12-month target
$9.00
▲ 78.2% upside

Based on 2 analysts who set a price target on OABI in the past 90 days. The average target is $9.00, with a high of $12.00 and a low of $6.00, compared with the last close of $5.05.

Low $6.00Avg $9.00High $12.00
Blue marker: last close $5.05
Highest target$12.00
Average target$9.00
Lowest target$6.00
Latest rating changes
Leerink PartnersMaintained
Oct 7Buy$12
StoneXMaintained
Oct 7Buy$6
HC Wainwright & Co.Reiterated
Aug 17Buy$11
DateFirmActionRatingPrice target
Oct 7Leerink PartnersMaintainedBuy$12
Oct 7StoneXMaintainedBuy$6
Aug 17HC Wainwright & Co.ReiteratedBuy$11
Loading…

Technical Analysis

OABI · as of the Nov 17 close · updated after every close
Uptrend

The stock is 1% above its 20 day and 6% above its 50 day average. It is 43% above its 200 day average, so the longer trend is still up. Momentum is neutral (RSI 54). The nearest support is the 20 day average at $5.01, and the nearest resistance the swing high (Oct 2) at $5.09.

Short trendBullish
Long trendBullish
MomentumNeutral
StretchNormal
VolatilityNormal, 6.5%/day
Key levels
$5.4552 week high+7.9%
$5.14Pivot R1+1.8%
$5.09Swing high (Oct 2)+0.8%
$5.05Last close
$5.0120 day average−0.8%
$4.98Pivot−1.4%
$4.89Pivot S1−3.2%
$4.79Swing low (Nov 5)−5.1%
$4.7750 day average−5.5%
$3.90100 day average−22.8%
$2.89200 day average−42.8%
$1.3552 week low−73.3%
Indicators
RSI (14)53.56Middle of its rangeNeutral
MACD0.08Below its signal lineBearish
Stochastic54.5Middle of its rangeNeutral
ADX (14)15.3No clear trend
Williams %R-36.4Oversold below −80, overbought above −20Neutral
CCI (20)-2.6Oversold below −100, overbought above 100Neutral
Rate of change−1.9%Change over 10 sessionsBearish
ATR (14)$0.33Typical daily range, 6.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for OABI

What happened before

See how OABI did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow OABI usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How OABI has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in OABI in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$132K
Largest print
$132K
Loading…

OABI Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲90 buying vs 60 selling
  • ▲Held by funds +7.5 pts
  • ▲Funds holding +31
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding162131+23.7%
In funds' top 1032+50.0%
Held by funds47.9%40.4%+7.5 pts
New / increased43 / 4720 / 58+15.4%
Reduced / sold out47 / 1333 / 16+22.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OABI institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OABI is in one of them and how their past OABI trades turned out.

OABI in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OABI in an article yet. Here's the latest on the wider market.

About OmniAb

OmniAb is a discovery research company based in Emeryville, California. It licenses its antibody discovery technology to pharmaceutical and biotech companies and academic institutions. The platform uses genetically engineered rats, mice and chickens whose immune systems produce fully human antibody candidates, which are then screened to find those suited to a partner's drug development. Customers use the resulting antibodies in their own therapy programs.

Headquarters
Emeryville, CA